Filing Details

Accession Number:
0001209191-23-011994
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-22 20:02:15
Reporting Period:
2023-02-18
Accepted Time:
2023-02-22 20:02:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1567514 Intra-Cellular Therapies Inc. ITCI Pharmaceutical Preparations (2834) 364742850
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1585697 J. Lawrence Hineline C/O Intra-Cellular Therapies, Inc.
430 East 29Th Street
New York NY 10016
Svp Of Finance Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-17 53,968 $12.73 53,968 No 4 M Direct
Common Stock Disposition 2023-02-17 52,279 $49.81 1,689 No 4 S Direct
Common Stock Disposition 2023-02-17 1,689 $50.59 0 No 4 S Direct
Common Stock Acquisiton 2023-02-18 10,443 $0.00 10,443 No 4 M Direct
Common Stock Disposition 2023-02-21 8,649 $46.54 1,794 No 4 S Direct
Common Stock Disposition 2023-02-21 800 $47.32 994 No 4 S Direct
Common Stock Disposition 2023-02-21 900 $48.72 94 No 4 S Direct
Common Stock Disposition 2023-02-21 94 $49.60 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2023-02-17 53,968 $0.00 53,968 $12.73
Common Stock Restricted Stock Units Disposition 2023-02-18 10,443 $0.00 10,443 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2029-01-07 No 4 M Direct
0 No 4 M Direct
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $50.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $50.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. Restricted stock units convert into common stock on a one-for-one basis.
  5. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.16 to $48.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.28 to $48.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  9. All shares underlying this option have vested.
  10. Each restricted stock unit represents a contingent right to receive one share of common stock.
  11. On February 18, 2020, the reporting person was granted 31,328 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.